HC Wainwright Has Optimistic View of Genelux FY2024 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for Genelux in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.84) for the year, up from their previous forecast of ($0.88). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $1.23 EPS.

Genelux Trading Up 1.7 %

GNLX opened at $3.08 on Thursday. The firm has a market cap of $106.38 million, a price-to-earnings ratio of -3.24 and a beta of -1.41. Genelux has a 12 month low of $1.60 and a 12 month high of $6.50. The stock has a fifty day moving average price of $4.06 and a 200-day moving average price of $3.10.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Friday, April 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.07).

Hedge Funds Weigh In On Genelux

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in shares of Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after buying an additional 89,854 shares during the last quarter. Marshall Wace LLP grew its holdings in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after purchasing an additional 52,958 shares during the last quarter. LPL Financial LLC increased its position in shares of Genelux by 72.3% during the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after purchasing an additional 39,516 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Genelux during the 3rd quarter valued at $59,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of Genelux during the 4th quarter valued at $51,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.